Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Canntab Therapeutics Limited (C:PILL)

Business Focus: Alternative Medicine

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for PILL within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jan 20, 2022 05:30 ET
CANNTAB OFFICIALLY LAUNCHES ITS ONLINE E-COMMERCE PLATFORM
TORONTO, Jan. 20, 2022 /PRNewswire/ - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the official launch of its online e-commerce platform and web site at www.Canntab.ca.
Read full article
Jan 20, 2022 05:30 ET
CANNTAB OFFICIALLY LAUNCHES ITS ONLINE E-COMMERCE PLATFORM
TORONTO, Jan. 20, 2022 /CNW/ - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the official launch of its online e-commerce platform and web site at www.Canntab.ca.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.92
--
--
Price to Sales - TTM
719.10
7.60
10.40
Price to Book - most recent quarter
13.65
1.70
2.43
Price to Cash Flow per share - TTM
--
10.76
13.52
Price to Free Cash Flow per share - TTM
--
27.45
27.39
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Dec 31, 202111,1789,198
Dec 15, 20211,980-26,473
Nov 30, 202128,453-96,099
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Canntab Therapeutics Limited is Canada-based biopharmaceutical company. The Company is focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The Company operates in one reportable operating, being engaged in the medical marijuana business. All property and equipment, right-of-use assets and intangible assets are located in Canada. Its hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions. Its products include INSTANT RELEASE - (IR Tablet), EXTENDED-RELEASE - (XR Tablet), and ORAL DISSOLVING - O.D. Tablet. It holds cannabis standard processing and sales for medical purposes license, a cannabis research license, and an industrial hemp license from health Canada.

See business summary

 

Twitter

Search (past week) for $PILL.CA

  • No tweets found